New Therapies for Diabetes

Clinical Cornerstone

Volumn 8, Issue 2, 2007, Pages 58-65

  Green, Dina E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; AMYLOID; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RHINOPHARYNGITIS; URINARY TRACT INFECTION; VOMITING; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GLUCOSE BLOOD LEVEL; PATHOPHYSIOLOGY; REVIEW;

AMYLOID; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASES; DISEASE PROGRESSION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; VENOMS;

EID: 41949099354     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)60008-9     Document Type: Article

References (25)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
3. Nathan D.M. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347 (2002) 1342-1349
4. Weyer C., Bogardus C., Mott D.M., and Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 (1999) 787-794
5. Del Prato S., and Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 36 (2004) 775-781
6. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
7. Pratley R.E., and Salsali A. Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Cur Med Res Opin 23 (2007) 919-931
8. Yoon K.H., Ko S.H., Cho J.H., et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88 (2003) 2300-2308
9. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
10. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
11. Buse J.B., Henry R.R., Han J., et al. for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
12. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
13. Zinman B., Hoogwerf B.J., Duran Garcia S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial [published correction appears in Ann Intern Med. 2007;146:896]. Ann Intern Med 146 (2007) 477-485
14. Amori R.E., Lau J., and Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298 (2007) 194-206
15. Heine R.J., Van Gaal L.F., Johns D., et al., for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 143 (2005) 559-569
16. Nauck M.A., Duran S., Kim D., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 50 (2007) 259-267
17. Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30 (2007) 1608-1610
18. Aschner P., Kipnes M.S., Lunceford J.K., et al., for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
19. Charbonnel B., Karasik A., Liu J., et al., for the Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 (2006) 2638-2643
20. Rosenstock J., Brazg R., Andryuk P.J., et al., for the Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28 (2006) 1556-1568
21. Jones M.C. Therapies for diabetes: Pramlintide and exenatide. Am Fam Physician 75 (2007) 1831-1835
22. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
23. Hollander P.A., Levy P., Fineman M.S., et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 26 (2003) 784-790
24. Ratner R.E., Dickey R., Fineman M., et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabetic Med 21 (2004) 1204-1212
25. Edelman S.V., Darsow T., and Frias J.P. Pramlintide in the treatment of diabetes. Int J Clin Pract 60 (2006) 1647-1653